Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 24
Summary
- Conditions
- Leukemia Myeloid Acute
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 2 years and 125 years
- Gender
- Both males and females
Description
Amendment 16: Based on the data indicating that ALT-803/IL-15 result in more modulation of the NK cells in vivo, the investigators performed a lead in cohort with ALT-803 replacing IL-2 at a dose of 10 mcg/kg SQ administered q5 days starting on the date of NK cell infusion. The first two patients tr...
Amendment 16: Based on the data indicating that ALT-803/IL-15 result in more modulation of the NK cells in vivo, the investigators performed a lead in cohort with ALT-803 replacing IL-2 at a dose of 10 mcg/kg SQ administered q5 days starting on the date of NK cell infusion. The first two patients treated in the ALT-803 lead in cohort experienced a set of symptoms consistent with cytokine release syndrome (CRS) including fevers, elevated markers of inflammation between days 10-14 after ML NK cell infusion. Based on the evidence of increased CD8 T cell activation, the in vitro data indicating that ALT-803 promoted recipient CD8 T cell expansion and killing of donor ML NK cells, and the lack of clinical responses using ALT-803, the lead in cohort was closed, and a decision was made to return to rhIL-2 support, mimicking the cytokine support utilized in the phase 2 portion of the trial. PLEASE NOTE: THE PEDIATRIC PORTION OF THE STUDY IS CLOSED TO FURTHER ENROLLMENT.
Tracking Information
- NCT #
- NCT01898793
- Collaborators
- American Society of Clinical Oncology
- American Society of Hematology
- Gabrielle's Angel Foundation
- The Leukemia and Lymphoma Society
- National Cancer Institute (NCI)
- ImmunityBio, Inc.
- Investigators
- Principal Investigator: Amanda Cashen, M.D. Washington University School of Medicine